Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Septin7 is essential in early hematopoiesis, but redundant at later stages.

Life science alliance·2026
Same author

MK2/p38/p53 Suppress Basal IL-1β and Non-Canonical NF-κB Signaling in Macrophages.

International journal of molecular sciences·2026
Same author

Beyond the Horizon: Rethinking Prostate Cancer Treatment Through Innovation and Alternative Strategies.

Cancers·2025
Same author

TLK1>Nek1 Axis Promotes Nuclear Retention and Activation of YAP with Implications for Castration-Resistant Prostate Cancer.

Cancers·2024
Same author

Regulation of Zfp36 by ISGF3 and MK2 restricts the expression of inflammatory cytokines during necroptosis stimulation.

Cell death & disease·2024
Same author

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer.

Biomedicines·2023

Related Experiment Video

Updated: May 13, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.0K

Targeting the TLK1-MK5 Axis Suppresses Prostate Cancer Metastasis.

Damilola Olatunde1, Omar Coronel Franco1, Matthias Gaestel2

  • 1Department of Biochemistry and Molecular Biology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.

Cancers
|April 14, 2025
PubMed
Summary

Targeting the TLK1-MK5 pathway inhibits prostate cancer (PCa) metastasis. Disrupting this signaling cascade reduces PCa cell motility and invasiveness, crucial for preventing cancer spread.

Keywords:
MAPKAPK5/MK5/PRAKTLK1/1BTRAMP miceprostate cancer metastasis

More Related Videos

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K

Related Experiment Videos

Last Updated: May 13, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.0K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Metastatic prostate cancer (PCa) causes most PCa deaths, with unclear spread mechanisms.
  • A novel TLK1-MK5 interaction promotes metastasis via a signaling cascade.
  • Increased TLK1/MK5 expression in metastatic PCa patients correlates with poor survival, especially after androgen deprivation therapy (ADT).

Purpose of the Study:

  • To investigate the role of the TLK1-MK5 axis in PCa metastasis.
  • To determine the effects of disrupting the TLK1>MK5 axis on PCa cell characteristics.

Main Methods:

  • Utilized pharmacologic and systemic approaches.
  • Employed genetically engineered mouse models.
  • Assessed outcomes using in vivo imaging (IVIS).

Main Results:

  • Targeting the TLK1>MK5 axis was essential for metastatic cell spread.
  • Disruption of the TLK1>MK5 axis inhibited PCa cell motility and invasiveness.
  • This pathway is critical for the development of age-related metastases.

Conclusions:

  • The TLK1-MK5 axis is a key driver of prostate cancer metastasis.
  • Inhibiting the TLK1-MK5 pathway represents a potential therapeutic strategy for metastatic PCa.
  • Further research into this axis could lead to improved treatments for advanced prostate cancer.